{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:26:26Z","timestamp":1773228386717,"version":"3.50.1"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00210-025-03961-y","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:24:32Z","timestamp":1741652672000},"page":"9737-9766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review"],"prefix":"10.1007","volume":"398","author":[{"given":"Kavita","family":"Sangwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parveen Kumar","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipasha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"18","key":"3961_CR1","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.3390\/cancers15184537","volume":"15","author":"M Abusalem","year":"2023","unstructured":"Abusalem M, Martiniova L, Soebianto S, DePalatis L, Ravizzini G (2023) Current status of radiolabeled monoclonal antibodies targeting PSMA for imaging and therapy. Cancers 15(18):4537. https:\/\/doi.org\/10.3390\/cancers15184537","journal-title":"Cancers"},{"issue":"9","key":"3961_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14740338.2023.2218085","volume":"22","author":"AK Abushanab","year":"2023","unstructured":"Abushanab AK, Mousa MT, Mustafa MAT, Qawaqzeh RA (2023) The efficacy and safety of capivasertib (azd5363) in the treatment of patients with solid tumor. A systematic review and meta-analysis of randomized clinical trials. Expert Opin Drug Saf 22(9):799\u2013805. https:\/\/doi.org\/10.1080\/14740338.2023.2218085","journal-title":"Expert Opin Drug Saf"},{"key":"3961_CR3","doi-asserted-by":"publisher","unstructured":"Agrawal G, Tushir S, Arora D, Sangwan K (2024) Artificial intelligence in pharmaceutical drug delivery. In2024 International Conference on Computational Intelligence and Computing Applications (ICCICA). 1:406\u2013410. https:\/\/doi.org\/10.1109\/ICCICA60014.2024.10585200","DOI":"10.1109\/ICCICA60014.2024.10585200"},{"issue":"11","key":"3961_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18632\/oncotarget.27489","volume":"11","author":"T Aikawa","year":"2020","unstructured":"Aikawa T, Togashi N, Iwanaga K, Okada H, Nishiya Y, Inoue S, Levis MJ, Isoyama T (2020) Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. Oncotarget 11(11):943. https:\/\/doi.org\/10.18632\/oncotarget.27489","journal-title":"Oncotarget"},{"key":"3961_CR5","unstructured":"American Cancer Society (2023) Cancer facts & figures 2023. Atlanta: American Cancer Society; 2023.https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf (accessed on January 5, 2024)"},{"key":"3961_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","volume":"63","author":"A Andrikopoulou","year":"2022","unstructured":"Andrikopoulou A, Chatzinikolaou S, Panourgias E, Kaparelou M, Liontos M, Dimopoulos MA, Zagouri F (2022) The emerging role of capivasertib in breast cancer. Breast 63:157\u2013167. https:\/\/doi.org\/10.1016\/j.breast.2022.03.018","journal-title":"Breast"},{"issue":"10","key":"3961_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A (2023) Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med 29(10):2570\u20132576. https:\/\/doi.org\/10.1038\/s41591-023-02589-w","journal-title":"Nat Med"},{"issue":"28","key":"3961_CR8","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.2217\/fon-2019-0370","volume":"15","author":"A Bardia","year":"2019","unstructured":"Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG (2019) EMERALD: phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncol 15(28):3209\u20133218. https:\/\/doi.org\/10.2217\/fon-2019-0370","journal-title":"Future Oncol"},{"issue":"3","key":"3961_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","volume":"6","author":"AME Br\u00f6ske","year":"2022","unstructured":"Br\u00f6ske AME, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ (2022) Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv 6(3):1025\u20131037. https:\/\/doi.org\/10.1182\/bloodadvances.2021005954","journal-title":"Blood Adv"},{"key":"3961_CR10","unstructured":"Center for Drug Evaluation and Research (CDER), advancing health through innovation: new drug therapy approvals. https:\/\/www.fda.gov\/media\/175253\/download?attachment (accessed on January 7, 2024)"},{"issue":"9","key":"3961_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/17474086.2021.1969911","volume":"14","author":"C Cerchione","year":"2021","unstructured":"Cerchione C, PeleteiroRaindo A, Mosquera Orgueira A, Mosquera Torre A, Bao Perez L, Marconi G, Isidori A, Perez Encinas MM, Martinelli G (2021) Safety of FLT3 inhibitors in patients with acute myeloid leukemia. Expert Rev Hematol 14(9):851\u2013865. https:\/\/doi.org\/10.1080\/17474086.2021.1969911","journal-title":"Expert Rev Hematol"},{"issue":"24","key":"3961_CR12","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NW, Rodr\u00edguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"issue":"1","key":"3961_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","volume":"15","author":"HT Chifotides","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S (2022) Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15(1):7. https:\/\/doi.org\/10.1186\/s13045-021-01157-4","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3961_CR14","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1016\/j.jtho.2021.01.251","volume":"16","author":"BC Cho","year":"2021","unstructured":"Cho BC, Doebele RC, Lin J, Nagasaka M, Baik C, Van Der Wekken A, Velcheti V, Lee KH, Liu S, Solomon B, Kao S (2021) MA11. 07 phase \u00bd TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors. J Thorac Oncol 16(3):S174\u2013S175. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.251","journal-title":"J Thorac Oncol"},{"issue":"16","key":"3961_CR15","doi-asserted-by":"publisher","first-page":"TPS6104","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS6104","volume":"41","author":"EE Cohen","year":"2023","unstructured":"Cohen EE, Le Tourneau C, Schaub R, Bartenstein M, Cheng L, Licitra LF (2023) Phase 2 trial of retifanlimab (anti\u2013PD\u20131) in combination with INCAGN02385 (anti\u2013LAG-3) and INCAGN02390 (anti\u2013TIM-3) as first-line treatment in patients with PD-L1\u2013positive recurrent\/metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 41(16):TPS6104. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS6104","journal-title":"J Clin Oncol."},{"issue":"21","key":"3961_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood.V120.21.1507.1507","volume":"120","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian HM, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis MJ (2012) Final results of a phase 1 study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of quizartinib (AC220) administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FLT3-ITD status. Blood 120(21):1507. https:\/\/doi.org\/10.1182\/blood.V120.21.1507.1507","journal-title":"Blood"},{"key":"3961_CR17","doi-asserted-by":"publisher","unstructured":"Crees ZD, Rettig MP, DiPersio JF (2023a) Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol 14. https:\/\/doi.org\/10.1177\/20406207231174304","DOI":"10.1177\/20406207231174304"},{"key":"3961_CR18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","volume":"29","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D (2023b) Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med 29:869\u2013879. https:\/\/doi.org\/10.1038\/s41591-023-02273-z","journal-title":"Nat Med"},{"key":"3961_CR19","doi-asserted-by":"publisher","first-page":"S1391","DOI":"10.1016\/j.annonc.2022.08.021","volume":"33","author":"NA Dasari","year":"2022","unstructured":"Dasari NA, Lonardi S, Garcia-Carbonero R, Fernandez ME, Yoshino T, Sobrero AF, Yao JC, Garc\u00eda-Alfonso P, Kocsis J, Gracian AC, Bianchi AS (2022) LBA25 FRESCO-2: a global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Ann Oncol 33:S1391\u2013S1392. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.021","journal-title":"Ann Oncol"},{"key":"3961_CR20","doi-asserted-by":"publisher","unstructured":"Davis DD, Ohana Z, Pham HM (2023) Pirtobrutinib: a novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma.\u00a0J Oncol Pharm Pract 10781552231216886. https:\/\/doi.org\/10.1177\/107815522312168","DOI":"10.1177\/107815522312168"},{"issue":"3","key":"3961_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE De Visser","year":"2023","unstructured":"De Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell."},{"issue":"6","key":"3961_CR22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2967\/jnumed.110.085613","volume":"52","author":"RA De Silva","year":"2011","unstructured":"De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S (2011) Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med 52(6):986\u2013993. https:\/\/doi.org\/10.2967\/jnumed.110.085613","journal-title":"J Nucl Med"},{"key":"3961_CR23","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673251030231004052822","author":"SK De","year":"2024","unstructured":"De SK (2024) Pirtobrutinib: first non-covalent tyrosine kinase inhibitor for treating relapsed or refractory mantle cell lymphoma in adults. Curr Med Chem. https:\/\/doi.org\/10.2174\/0109298673251030231004052822","journal-title":"Curr Med Chem"},{"key":"3961_CR24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S (2023) Elranatamab: first approval. Drugs 83:1621\u20131627. https:\/\/doi.org\/10.1007\/s40265-023-01954-w","journal-title":"Drugs"},{"issue":"10","key":"3961_CR25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","volume":"8","author":"A Drilon","year":"2018","unstructured":"Drilon A, Ou SHI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D (2018) Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations. Cancer Discov 8(10):1227\u20131236. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0484","journal-title":"Cancer Discov"},{"key":"3961_CR26","doi-asserted-by":"publisher","unstructured":"Ellis R, Weiss A (2023) Human vaccines & immunotherapeutics: news June 2023.\u00a0Human Vaccin Immunother. 19(2). https:\/\/doi.org\/10.1080\/21645515.2023.2234215","DOI":"10.1080\/21645515.2023.2234215"},{"key":"3961_CR27","doi-asserted-by":"publisher","first-page":"123384","DOI":"10.1016\/j.ijpharm.2023.123384","volume":"645","author":"R Elsanhoury","year":"2023","unstructured":"Elsanhoury R, Alasmari A, Parupathi P, Jumaa M, Al-Fayoumi S, Kumar A, Khashan R, Nazzal S, Fayyad AA (2023) AI & experimental-based discovery and preclinical IND-enabling studies of selective BMX inhibitors for development of cancer therapeutics. Int J Pharm 645:123384","journal-title":"Int J Pharm"},{"key":"3961_CR28","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Hernandez IB, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ, Verploegen S (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EbioMedicine 52:102625","journal-title":"EbioMedicine"},{"issue":"10388","key":"3961_CR29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC (2023) Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10388):1571\u20131583. https:\/\/doi.org\/10.1016\/S0140-6736(23)00464-6","journal-title":"Lancet"},{"issue":"36","key":"3961_CR30","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.2217\/fon-2022-0976","volume":"18","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ (2022) BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma. Future Oncol 18(36):3961\u20133969. https:\/\/doi.org\/10.2217\/fon-2022-0976","journal-title":"Future Oncol"},{"issue":"1","key":"3961_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41698-022-00308-1","volume":"6","author":"N Federman","year":"2022","unstructured":"Federman N (2022) Molecular pathogenesis of desmoids tumor and the role of \u03b3-secretase inhibition. NPJ Precis Oncol 6(1):62. https:\/\/doi.org\/10.1038\/s41698-022-00308-1","journal-title":"NPJ Precis Oncol"},{"issue":"14","key":"3961_CR32","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","volume":"83","author":"JE Frampton","year":"2023","unstructured":"Frampton JE (2023) Epcoritamab: first approval. Drugs 83(14):1331\u20131340. https:\/\/doi.org\/10.1007\/s40265-023-01930-4","journal-title":"Drugs"},{"issue":"4","key":"3961_CR33","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.xphs.2021.12.019","volume":"111","author":"N Frances","year":"2022","unstructured":"Frances N, Bacac M, Bray-French K, Christen F, Hinton H, Husar E, Quackenbush E, Sch\u00e4fer M, Schick E, Van De Vyver A, Richter WF (2022) Novel in vivo and in vitro pharmacokinetic\/pharmacodynamic-based human starting dose selection for glofitamab. J Pharm Sci 111(4):1208\u20131218. https:\/\/doi.org\/10.1016\/j.xphs.2021.12.019","journal-title":"J Pharm Sci"},{"issue":"17","key":"3961_CR34","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1080\/14656566.2020.1801637","volume":"21","author":"A Garcia-Horton","year":"2020","unstructured":"Garcia-Horton A, Yee KW (2020) Quizartinib for the treatment of acute myeloid leukemia. Expert Opin Pharmacother 21(17):2077\u20132090. https:\/\/doi.org\/10.1080\/14656566.2020.1801637","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"3961_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood.2022018674","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J, Wu W (2023) Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood 142(1):62\u201372. https:\/\/doi.org\/10.1182\/blood.2022018674","journal-title":"Blood"},{"issue":"10","key":"3961_CR36","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Sch\u00f6ffski P, Van Der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S (2023) Nirogacestat, a \u03b3-secretase inhibitor for desmoids tumors. N Engl J Med 388(10):898\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2210140","journal-title":"N Engl J Med"},{"issue":"2","key":"3961_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s40495-024-00351-5","volume":"10","author":"PK Goyal","year":"2024","unstructured":"Goyal PK, Sangwan K (2024a) Pharmacological profile of FDA-approved orphan drugs in the year 2022. Curr Pharmacol Rep 10(2):96\u2013120. https:\/\/doi.org\/10.1007\/s40495-024-00351-5","journal-title":"Curr Pharmacol Rep"},{"key":"3961_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01268-3","author":"PK Goyal","year":"2024","unstructured":"Goyal PK, Sangwan K (2024b) Tarlatamab-dlle: a new hope for patients with extensive-stage small-cell lung cancer. Curr Treat Options in Oncol. https:\/\/doi.org\/10.1007\/s11864-024-01268-3","journal-title":"Curr Treat Options in Oncol"},{"key":"3961_CR39","doi-asserted-by":"publisher","first-page":"100140","DOI":"10.1016\/j.hsr.2023.100140","volume":"9","author":"PK Goyal","year":"2023","unstructured":"Goyal PK, Khurana S, Mittal A (2023) Hydrogel-bound cytotoxic drug delivery system for breast cancer. Health Sci Rev 9:100140. https:\/\/doi.org\/10.1016\/j.hsr.2023.100140","journal-title":"Health Sci Rev"},{"key":"3961_CR40","doi-asserted-by":"publisher","unstructured":"Goyal PK, Vats S (2023) Enzymatically degradable linkers. Polymer-drug conjugates 279\u2013313. https:\/\/doi.org\/10.1016\/B978-0-323-91663-9.00002-3","DOI":"10.1016\/B978-0-323-91663-9.00002-3"},{"key":"3961_CR41","unstructured":"Goyal PK, Shekhar S, Rishi K (2011) Hatch Waxman act and generic drugs: a review. J Pharm Biomed Sci 8, 22:1\u20136. https:\/\/www.scribd.com\/document\/645366214\/Hatch-Waxman-Act-and-Generic-Drugs-pdf"},{"key":"3961_CR42","doi-asserted-by":"publisher","first-page":"S686","DOI":"10.1016\/j.annonc.2023.09.2280","volume":"34","author":"G Grignani","year":"2023","unstructured":"Grignani G, Rutkowski P, Lebbe C, Guida M, Marqueste CG, De Braud FGM, Spagnolo F, Burgess M, Montaudie H, Depenni R, Spada F (2023) 1146P updated results from POD1UM-201: a phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC). Ann Oncol 34:S686. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2280","journal-title":"Ann Oncol"},{"issue":"8","key":"3961_CR43","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2023.2236303","volume":"23","author":"S Grosicki","year":"2023","unstructured":"Grosicki S, Bednarczyk M, Kociszewska K (2023) Elranatamab: a new promising BispAb in multiple myeloma treatment. Expert Rev Anticancer Ther 23(8):775\u2013782. https:\/\/doi.org\/10.1080\/14737140.2023.2236303","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"3961_CR44","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727","journal-title":"Am J Cancer Res"},{"issue":"5","key":"3961_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40291-023-00665-y","volume":"27","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023) Flotufolastat F 18: diagnostic first approval. Mol Diagn Ther 27(5):631\u2013636. https:\/\/doi.org\/10.1007\/s40291-023-00665-y","journal-title":"Mol Diagn Ther"},{"issue":"7","key":"3961_CR46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"SJ Howell","year":"2022","unstructured":"Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 23(7):851\u2013864. https:\/\/doi.org\/10.1016\/S1470-2045(22)00284-4","journal-title":"Lancet Oncol"},{"key":"3961_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40265-023-01861-0","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Elacestrant: first approval. Drugs 83:555\u2013561. https:\/\/doi.org\/10.1007\/s40265-023-01861-0","journal-title":"Drugs"},{"key":"3961_CR48","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2020.38.15_suppl.8009","volume":"38","author":"M Hutchings","year":"2020","unstructured":"Hutchings M, Lugtenburg P, Mous R, Clausen MR, Chamuleau M, Linton K, Rule S, Lopez JS, Oliveri RS, DeMarco D (2020a) Epcoritamab (GEN3013; DuoBody-CD3\u00d7 CD20) to induce complete response in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (B-NHL): complete dose escalation data and efficacy results from a phase I\/II trial. J Clin Oncol 38:8009","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"3961_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-133820","volume":"136","author":"M Hutchings","year":"2020","unstructured":"Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau ME, Lewis DJ, Balari AS, Cunningham D, Oliveri RS, DeMarco D (2020b) Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data. Blood 136(Supplement 1):45\u201346. https:\/\/doi.org\/10.1182\/blood-2020-133820","journal-title":"Blood"},{"issue":"18","key":"3961_CR50","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Mart\u00ednez-Lopez J, Crump M, Thomas DN, Morcos PN (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 39(18):1959. https:\/\/doi.org\/10.1200\/JCO.20.03175","journal-title":"J Clin Oncol"},{"key":"3961_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Sig Transduct Target Ther 5:166. https:\/\/doi.org\/10.1038\/s41392-020-00280-x","journal-title":"Sig Transduct Target Ther"},{"issue":"12","key":"3961_CR52","doi-asserted-by":"publisher","first-page":"1044328","DOI":"10.3389\/fonc.2022.1044328","volume":"24","author":"Y Jin","year":"2022","unstructured":"Jin Y, Li J, Shen L, Xu J, Zhang Y, Zhang J, Pan H, Qu X, Chen Y, Zhang Q, Li J, Sun M, Qin S (2022) A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer. Front Oncol 24(12):1044328. https:\/\/doi.org\/10.3389\/fonc.2022.1044328","journal-title":"Front Oncol"},{"key":"3961_CR53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40265-023-01884-7","volume":"83","author":"C Kang","year":"2023","unstructured":"Kang C (2023) Retifanlimab: first approval. Drugs 83:731\u2013737. https:\/\/doi.org\/10.1007\/s40265-023-01884-7","journal-title":"Drugs"},{"issue":"6","key":"3961_CR54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023a) Pirtobrutinib: first approval. Drugs 83(6):547\u2013553. https:\/\/doi.org\/10.1007\/s40265-023-01860-1","journal-title":"Drugs"},{"issue":"15","key":"3961_CR55","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023b) Talquetamab: first approval. Drugs 83(15):1439\u20131445. https:\/\/doi.org\/10.1007\/s40265-023-01945-x","journal-title":"Drugs"},{"key":"3961_CR56","doi-asserted-by":"publisher","unstructured":"Khurana S, Sharma S, Goyal PK (2025) Tumor microenvironment as a target for developing anticancer hydrogels. Drug Dev Ind Pharm 1\u201320. https:\/\/doi.org\/10.1080\/03639045.2025.2455424","DOI":"10.1080\/03639045.2025.2455424"},{"issue":"14","key":"3961_CR57","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.55522\/jmpas.V12I4.5491","volume":"12","author":"PS Krishna","year":"2023","unstructured":"Krishna PS, Eswarudu MM, Babu PS, Likhitha T, Venkatesh N, Poojitha C, Sujana K, Gopaiah B (2023) A review on analytical profile for newly FDA approved drugs in 2023. J Med Pharm Allied Sci 12(14):5955\u20135961. https:\/\/doi.org\/10.55522\/jmpas.V12I4.5491","journal-title":"J Med Pharm Allied Sci"},{"key":"3961_CR58","doi-asserted-by":"publisher","unstructured":"Kuo PH, Hermsen R, Penny R, Postema EJ (2023) Quantitative and qualitative assessment of urinary activity of 18F-flotufolastat-PET\/CT in patients with prostate cancer: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies.\u00a0Mol Imaging Biol 1\u20138. https:\/\/doi.org\/10.1007\/s11307-023-01867-w","DOI":"10.1007\/s11307-023-01867-w"},{"key":"3961_CR59","doi-asserted-by":"publisher","unstructured":"Lap CJ, Abrahim MS, Nassereddine S (2023) Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia\u00a0Ann Hematol. 1\u201315. https:\/\/doi.org\/10.1007\/s00277-023-05545-3","DOI":"10.1007\/s00277-023-05545-3"},{"issue":"6","key":"3961_CR60","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.3390\/ijms24065840","volume":"24","author":"D Lavacchi","year":"2023","unstructured":"Lavacchi D, Roviello G, Guidolin A, Romano S, Venturini J, Caliman E, Vannini A, Giommoni E, Pellegrini E, Brugia M, Pillozzi S (2023) Evaluation of fruquintinibin the continuum of care of patients with colorectal cancer. Int J Mol Sci 24(6):5840. https:\/\/doi.org\/10.3390\/ijms24065840","journal-title":"Int J Mol Sci"},{"issue":"S1","key":"3961_CR61","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.5045\/br.2023.2023012","volume":"58","author":"SE Lee","year":"2023","unstructured":"Lee SE (2023) Novel therapeutics for myelofibrosis. Blood Res 58(S1):S13\u2013S19. https:\/\/doi.org\/10.5045\/br.2023.2023012","journal-title":"Blood Res"},{"issue":"9","key":"3961_CR62","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1111\/bcp.14022","volume":"85","author":"J Li","year":"2019","unstructured":"Li J, Kankam M, Trone D, Gammon G (2019) Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Br J Clin Pharmacol 85(9):2108\u20132117. https:\/\/doi.org\/10.1111\/bcp.14022","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"3961_CR63","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/pharmaceutics13111761","volume":"13","author":"W Li","year":"2021","unstructured":"Li W, Sparidans RW, Lebre MC, Beijnen JH, Schinkel AH (2021) ABCB1 and ABCG2 control brain accumulation and intestinal disposition of the novel ROS1\/TRK\/ALK inhibitor repotrectinib, while oatp1a\/1b, abcg2, and cyp3a limit its oral availability. Pharmaceutics 13(11):1761. https:\/\/doi.org\/10.3390\/pharmaceutics13111761","journal-title":"Pharmaceutics"},{"issue":"1","key":"3961_CR64","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH (2024) Guan XY (2024) Exploring treatment options in cancer: tumor treatment strategies. Sig Transduct Target Ther 9(1):175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7","journal-title":"Sig Transduct Target Ther"},{"issue":"18","key":"3961_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/01.COT.0000978960.75592.93","volume":"45","author":"A Lovell","year":"2023","unstructured":"Lovell A (2023) Epcoritamab-bysp (Epkinly\u2122). Oncol times 45(18):11. https:\/\/doi.org\/10.1097\/01.COT.0000978960.75592.93","journal-title":"Oncol times"},{"key":"3961_CR66","unstructured":"MagnetisMM-3: Study OfElranatamab (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one PI, one ImiD, and one anti-CD38 mAb. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04649359 (Accessed on January 5, 2024)"},{"key":"3961_CR67","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40261-019-00881-7","volume":"40","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2020","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Rodr\u00edguez-Mac\u00edas G, Rodr\u00edguez-Veiga R, Boluda B, Montesinos P (2020) Practical considerations for treatment of relapsed\/refractory FLT3-ITD acute myeloid leukaemia with quizartinib: illustrative case reports. Clin Drug Investig 40:227\u2013235. https:\/\/doi.org\/10.1007\/s40261-019-00881-7","journal-title":"Clin Drug Investig"},{"key":"3961_CR68","unstructured":"Mastroianni B (2023) Oncology\/cancer: 2023 advancements and breakthroughs. https:\/\/www.healthline.com\/health-news\/oncology-cancer-2023-advancements-and-breakthroughs#Strides-in-cancer-survival (accessed on January 5, 2024)"},{"issue":"4","key":"3961_CR69","doi-asserted-by":"publisher","first-page":"e608","DOI":"10.1002\/onco.13627","volume":"26","author":"TR McCaw","year":"2021","unstructured":"McCaw TR, Inga E, Chen H, Jaskula-Sztul R, Dudeja V, Bibb JA, Ren B, Rose JB (2021) Gamma secretase inhibitors in cancer: a current perspective on clinical performance. Oncologist 26(4):e608\u2013e621. https:\/\/doi.org\/10.1002\/onco.13627","journal-title":"Oncologist"},{"issue":"9","key":"3961_CR70","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/cpdd.1307","volume":"12","author":"C Miller","year":"2023","unstructured":"Miller C, Sommavilla R, Barry ST, Eberlein C, Morris T, Wadsworth I, Cullberg M (2023) Pharmacokinetics of the AKT serine\/threonine protein kinase inhibitor, capivasertib, administered to healthy volunteers in the presence and absence of the CYP3A4 inhibitor itraconazole. Clin Pharmacol Drug Develop 12(9):856\u2013862. https:\/\/doi.org\/10.1002\/cpdd.1307","journal-title":"Clin Pharmacol Drug Develop"},{"issue":"13","key":"3961_CR71","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","volume":"62","author":"A Minson","year":"2021","unstructured":"Minson A, Dickinson M (2021) Glofitamab CD20-TCB bispecific antibody. Leuk Lymphoma 62(13):3098\u20133108. https:\/\/doi.org\/10.1080\/10428194.2021.1953016","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"3961_CR72","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1158\/1535-7163.MCT-21-0632","volume":"20","author":"BW Murray","year":"2021","unstructured":"Murray BW, Rogers E, Zhai D, Deng W, Chen X, Sprengeler PA, Zhang X, Graber A, Reich SH, Stopatschinskaja S, Solomon B (2021) Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and resistant mutations. Mol Cancer Ther 20(12):2446\u20132456. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0632","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"3961_CR73","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1080\/10428194.2019.1602263","volume":"60","author":"K Naqvi","year":"2019","unstructured":"Naqvi K, Ravandi F (2019) FLT3 inhibitor quizartinib (AC220). Leuk Lymphoma 60(8):1866\u20131876. https:\/\/doi.org\/10.1080\/10428194.2019.1602263","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3961_CR74","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1470-2045(19)30857-5","volume":"21","author":"A Nasrazadani","year":"2020","unstructured":"Nasrazadani A, Brufsky AM (2020) Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol 21(3):318\u2013319. https:\/\/doi.org\/10.1016\/S1470-2045(19)30857-5","journal-title":"Lancet Oncol"},{"key":"3961_CR75","doi-asserted-by":"publisher","first-page":"1007762","DOI":"10.3389\/fphar.2022.1007762","volume":"13","author":"K Nurgali","year":"2022","unstructured":"Nurgali K, Rudd JA, Was H, Abalo R (2022) Editorial: Cancer therapy: the challenge of handling a double-edged sword. Front Pharmacol 13:1007762. https:\/\/doi.org\/10.3389\/fphar.2022.1007762","journal-title":"Front Pharmacol"},{"key":"3961_CR76","unstructured":"Oncology cancer drug market. https:\/\/straitsresearch.com\/report\/oncology-cancer-drugs-market (accessed on January 5, 2024)"},{"issue":"16","key":"3961_CR77","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.3390\/cancers14163972","volume":"14","author":"C Peterson","year":"2022","unstructured":"Peterson C, Denlinger N, Yang Y (2022) Recent advances and challenges in cancer immunotherapy. Cancers 14(16):3972. https:\/\/doi.org\/10.3390\/cancers14163972","journal-title":"Cancers"},{"key":"3961_CR78","unstructured":"Pharmaceutical oncology drugs market (2024) https:\/\/www.fortunebusinessinsights.com\/oncology-drugs-market-103431 (accessed on January 5, 2024)"},{"issue":"15","key":"3961_CR79","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D (2020) A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135(15):1232\u20131243. https:\/\/doi.org\/10.1182\/blood.2019003342","journal-title":"Blood"},{"issue":"5","key":"3961_CR80","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.3390\/ijms24054393","volume":"24","author":"M Rebolledo-Bustillo","year":"2023","unstructured":"Rebolledo-Bustillo M, Garcia-Gomez D, D\u00e1vila EM, Castro ME, Caballero NA, Melendez FJ, Baizabal-Aguirre VM, Sanchez-Gaytan BL, Perez-Aguilar JM (2023) Structural basis of the binding mode of the antineoplastic compound motixafortide (BL-8040) in the CXCR4 chemokine receptor. Int J Mol Sci 24(5):4393. https:\/\/doi.org\/10.3390\/ijms24054393","journal-title":"Int J Mol Sci"},{"key":"3961_CR81","doi-asserted-by":"publisher","DOI":"10.2174\/0115733947289878240126111236","author":"K Sangwan","year":"2024","unstructured":"Sangwan K, Goyal PK (2024) Anti-cancer potential of phytoflavonoidal drugs against gynecological cancer. Curr Cancer Ther Rev. https:\/\/doi.org\/10.2174\/0115733947289878240126111236","journal-title":"Curr Cancer Ther Rev"},{"issue":"2s","key":"3961_CR82","doi-asserted-by":"publisher","first-page":"s453","DOI":"10.5530\/ijper.57.2s.53","volume":"57","author":"K Sangwan","year":"2023","unstructured":"Sangwan K, Singh B (2023) Antiproliferative activity of novel imatinib analog as potential anticancer agents, synthesis and in vitro screening. Ind J Pharm Edu Res 57(2s):s453\u2013s458","journal-title":"Ind J Pharm Edu Res"},{"key":"3961_CR83","doi-asserted-by":"publisher","DOI":"10.2174\/1566524023666230622151034","author":"K Sangwan","year":"2023","unstructured":"Sangwan K, Sharma V, Goyal PK (2023a) Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: a review. Curr Mol Med. https:\/\/doi.org\/10.2174\/1566524023666230622151034","journal-title":"Curr Mol Med"},{"issue":"3","key":"3961_CR84","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40495-023-00316-0","volume":"9","author":"K Sangwan","year":"2023","unstructured":"Sangwan K, Khurana S, Dhakla P (2023b) Imatinib analogs in chronic myeloid leukemia: a systematic qualitative review. Curr Pharmacol Rep 9(3):99\u2013116. https:\/\/doi.org\/10.1007\/s40495-023-00316-0","journal-title":"Curr Pharmacol Rep"},{"issue":"3","key":"3961_CR85","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/IJ9.0000000000000116","volume":"8","author":"A Shaukat","year":"2023","unstructured":"Shaukat A, Khan A, Riaz R, Batool UEA, Malikzai A (2023) Retifanlimab: a breakthrough for the management of Merkel cell carcinoma. Int J Surg Oncol 8(3):18\u201320. https:\/\/doi.org\/10.1097\/IJ9.0000000000000116","journal-title":"Int J Surg Oncol"},{"issue":"16","key":"3961_CR86","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.1200\/JCO.2023.41.16_suppl.8027","volume":"41","author":"T Shearer","year":"2023","unstructured":"Shearer T, Williams RL, Johnson M, Cendrowicz E, Leonowens C, Smith M, Baughman T, Breitbach CJ, Smith LM, Cheng S (2023) Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects. J Clin Oncol 41(16):8027. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8027","journal-title":"J Clin Oncol"},{"issue":"5","key":"3961_CR87","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","volume":"67","author":"IM Shih","year":"2007","unstructured":"Shih IM, Wang TL (2007) Notch signaling, \u03b3-secretase inhibitors, and cancer therapy. Cancer Res 67(5):1879\u20131882. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3958","journal-title":"Cancer Res"},{"issue":"16","key":"3961_CR88","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s40265-018-0998-z","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M (2018) Fruquintinib: first global approval. Drugs 78(16):1757\u20131761. https:\/\/doi.org\/10.1007\/s40265-018-0998-z","journal-title":"Drugs"},{"key":"3961_CR89","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","volume":"83","author":"M Shirley","year":"2023","unstructured":"Shirley M (2023) Glofitamab: first approval. Drugs 83:935\u2013941. https:\/\/doi.org\/10.1007\/s40265-023-01894-5","journal-title":"Drugs"},{"issue":"20","key":"3961_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41571-023-00790-x","volume":"579","author":"P Sidaway","year":"2023","unstructured":"Sidaway P (2023) Capivasertib delays disease progression. Nat Rev Clin Oncol 579(20):1\u20131. https:\/\/doi.org\/10.1038\/s41571-023-00790-x","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3961_CR91","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics, 2023. CA: Cancer J Clin. 73(3):233\u2013254. https:\/\/doi.org\/10.3322\/caac.21772","journal-title":"CA: Cancer J Clin."},{"issue":"25","key":"3961_CR92","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A (2016) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127(25):3225\u20133236. https:\/\/doi.org\/10.1182\/blood-2016-01-691162","journal-title":"Blood"},{"issue":"10","key":"3961_CR93","doi-asserted-by":"publisher","first-page":"e28636","DOI":"10.1002\/pbc.28636","volume":"67","author":"T Takahashi","year":"2020","unstructured":"Takahashi T, Prensner JR, Robson CD, Janeway KA, Weigel BJ (2020) Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: report of four pediatric\/young adult cases. Pediatr Blood Cancer 67(10):e28636. https:\/\/doi.org\/10.1002\/pbc.28636","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"3961_CR94","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.3324\/haematol.2022.282612","volume":"108","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Pardanani A, Gangat N (2023) Momelotinib (JAK1\/JAK2\/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica 108(11):2919. https:\/\/doi.org\/10.3324\/haematol.2022.282612","journal-title":"Haematologica"},{"issue":"26","key":"3961_CR95","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1182\/blood.2023020240","volume":"141","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Tam CS (2023) Pirtobrutinib: a new hope for patients with BTK-inhibitor refractory lymphoproliferative disorders. Blood 141(26):3137\u20133142. https:\/\/doi.org\/10.1182\/blood.2023020240","journal-title":"Blood"},{"issue":"10","key":"3961_CR96","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4155\/fmc-2019-0365","volume":"12","author":"L Tong","year":"2020","unstructured":"Tong L, Li X, Hu Y, Liu T (2020) Recent advances in FLT3 inhibitors for acute myeloid leukemia. Future Med Chem 12(10):961\u2013981. https:\/\/doi.org\/10.4155\/fmc-2019-0365","journal-title":"Future Med Chem"},{"issue":"20","key":"3961_CR97","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2217\/fon-2022-0276","volume":"18","author":"D Tremblay","year":"2022","unstructured":"Tremblay D, Mesa R (2022) Momelotinib for the treatment of myelofibrosis with anemia. Future Oncol 18(20):2559\u20132571. https:\/\/doi.org\/10.2217\/fon-2022-0276","journal-title":"Future Oncol"},{"issue":"22","key":"3961_CR98","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S (2023) Capivasertib in hormone receptor\u2013positive advanced breast cancer. N Engl J Med 388(22):2058\u20132070. https:\/\/doi.org\/10.1056\/NEJMoa2214131","journal-title":"N Engl J Med"},{"key":"3961_CR99","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/OTT.S400563","volume":"16","author":"L Varella","year":"2023","unstructured":"Varella L, Cristofanilli M (2023) Evaluating elacestrant in the management of ER-positive, HER2-negative advanced breast cancer: evidence to date. Onco Targets Ther 16:189\u2013196. https:\/\/doi.org\/10.2147\/OTT.S400563","journal-title":"Onco Targets Ther"},{"issue":"8","key":"3961_CR100","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CP Verkleij","year":"2021","unstructured":"Verkleij CP, Broekmans ME, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 5(8):2196\u20132215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805","journal-title":"Blood Adv"},{"issue":"10373","key":"3961_CR101","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401(10373):269\u2013280. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0","journal-title":"Lancet"},{"issue":"10","key":"3961_CR102","doi-asserted-by":"publisher","first-page":"e2013770","DOI":"10.1001\/jamanetworkopen.2020.13770","volume":"3","author":"Z Wang","year":"2020","unstructured":"Wang Z, Ying J, Xu J, Yuan P, Duan J, Bai H, Guo C, Li L, Yang Z, Wan R, Fei K (2020) Safety, antitumor activity, and pharmacokinetics of toripalimab, a programmed cell death 1 inhibitor, in patients with advanced non\u2013small cell lung cancer: a phase 1 trial. JAMA 3(10):e2013770\u2013e2013770. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13770","journal-title":"JAMA"},{"issue":"7","key":"3961_CR103","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, Yuan XL, Huang HX, Chen Y, Dai GH, Shi JH, Shen L, Yang SJ, Shu YQ, Liu YP, Wang W, Wu H, Feng H, Yao S, Xu RH (2021) Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol 39(7):704\u2013712. https:\/\/doi.org\/10.1200\/JCO.20.02712","journal-title":"J Clin Oncol"},{"issue":"10","key":"3961_CR104","doi-asserted-by":"publisher","first-page":"11149","DOI":"10.1002\/cam4.5698","volume":"12","author":"Q Wang","year":"2023","unstructured":"Wang Q, Shao X, Zhang Y, Zhu M, Wang FX, Mu J, Li J, Yao H, Chen K (2023) Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 12(10):11149\u201311165. https:\/\/doi.org\/10.1002\/cam4.5698","journal-title":"Cancer Med"},{"key":"3961_CR105","doi-asserted-by":"publisher","first-page":"116124","DOI":"10.1016\/j.ejmech.2024.116124","volume":"265","author":"YT Wang","year":"2024","unstructured":"Wang YT, Yang PC, Zhang YF, Sun JF (2024) Synthesis and clinical application of new drugs approved by FDA in 2023. Eur J Med Chem 265:116124. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116124","journal-title":"Eur J Med Chem"},{"issue":"5","key":"3961_CR106","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2217\/fon-2016-0417","volume":"13","author":"EF Winton","year":"2017","unstructured":"Winton EF, Kota V (2017) Momelotinib in myelofibrosis: JAK1\/2 inhibitor with a role in treating and understanding the anemia. Future Oncol 13(5):395\u2013407. https:\/\/doi.org\/10.2217\/fon-2016-0417","journal-title":"Future Oncol"},{"issue":"27","key":"3961_CR107","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1021\/acs.biochem.9b00401","volume":"58","author":"MS Wolfe","year":"2019","unstructured":"Wolfe MS (2019) Structure and function of the \u03b3-secretase complex. Biochem 58(27):2953\u20132966. https:\/\/doi.org\/10.1021\/acs.biochem.9b00401","journal-title":"Biochem"},{"key":"3961_CR108","unstructured":"Worldwide cancer data (2022) World Cancer Research Fund International.https:\/\/www.wcrf.org\/cancer-trends\/worldwide-cancer-data\/ (accessed on January 5, 2024)"},{"issue":"10","key":"3961_CR109","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.3390\/cancers14102518","volume":"14","author":"L Wu","year":"2022","unstructured":"Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V (2022) Bispecific BCMA-CD3 antibodies block multiple myeloma tumor growth. Cancers 14(10):2518. https:\/\/doi.org\/10.3390\/cancers14102518","journal-title":"Cancers"},{"key":"3961_CR110","first-page":"291","volume":"6","author":"Y Xu","year":"2022","unstructured":"Xu Y, Shen H, Wang Y, Tan Q, Chen X (2022) Efficacy and safety of fruquintinib in treatment of elderly patients with advanced metastatic colorectal cancer who failed chemotherapy. Cancer Res Clin 6:291\u2013294","journal-title":"Cancer Res Clin"},{"issue":"11","key":"3961_CR111","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/14740338.2023.2274426","volume":"22","author":"AT Yang","year":"2023","unstructured":"Yang AT, Laetsch TW (2023) Safety of current treatment options for NTRK fusion-positive cancers. Expert Opin Drug Saf 22(11):1073\u20131089. https:\/\/doi.org\/10.1080\/14740338.2023.2274426","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"3961_CR112","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-19-2777","volume":"26","author":"MR Yun","year":"2020","unstructured":"Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ (2020) Repotrectinib exhibits potent antitumor activity in treatment-na\u00efve and solvent-front\u2013mutant ROS1-rearranged non\u2013small cell lung cancer. Clin Cancer Res 26(13):3287\u20133295. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2777","journal-title":"Clin Cancer Res"},{"key":"3961_CR113","doi-asserted-by":"publisher","first-page":"730666","DOI":"10.3389\/fimmu.2021.730666","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hao B, Geng Z, Geng Q (2022) Toripalimab: the first domestic anti-tumor PD-1 antibody in China. Front Immunol 12:730666. https:\/\/doi.org\/10.3389\/fimmu.2021.730666","journal-title":"Front Immunol"},{"key":"3961_CR114","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40495-023-00346-8","volume":"9","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Roy A, Kondic AG (2023) Time-dependent pharmacokinetics of immune checkpoint inhibitors and their implications and considerations for exposure\u2013response analysis. Curr Pharmacol Rep 9:397\u2013403. https:\/\/doi.org\/10.1007\/s40495-023-00346-8","journal-title":"Curr Pharmacol Rep"},{"issue":"3","key":"3961_CR115","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1124\/dmd.117.078899","volume":"46","author":"J Zheng","year":"2018","unstructured":"Zheng J, Xin Y, Zhang J, Subramanian R, Murray BP, Whitney JA, Warr MR, Ling J, Moorehead L, Kwan E, Hemenway J (2018) Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite\u2014resolution for clinical development. Drug Metab Dispos 46(3):237\u2013247. https:\/\/doi.org\/10.1124\/dmd.117.078899","journal-title":"Drug Metab Dispos"},{"key":"3961_CR116","doi-asserted-by":"publisher","first-page":"1227049","DOI":"10.3389\/fnins.2023.1227049","volume":"17","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Li H (2023) Neurological adverse events associated with PD-1\/PD-L1 immune checkpoint inhibitors. Front Neurosci 17:1227049. https:\/\/doi.org\/10.3389\/fnins.2023.1227049","journal-title":"Front Neurosci"},{"key":"3961_CR117","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2147\/DDDT.S198950","volume":"13","author":"F Zhou","year":"2019","unstructured":"Zhou F, Ge Z, Chen B (2019) Quizartinib (AC220): a promising option for acute myeloid leukemia. Drug des Devel Ther 13:1117\u20131125. https:\/\/doi.org\/10.2147\/DDDT.S198950","journal-title":"Drug des Devel Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03961-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:30:09Z","timestamp":1757143809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03961-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":117,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3961"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03961-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}